Overview
Pennant Q2 2025 revenue grows 30.1% yr/yr, beating analyst expectations
Adjusted EPS for Q2 meets analyst expectations at $0.27
Adjusted EBITDA for Q2 rises to $28.2 mln, beating estimates
Outlook
Co, provides home health, hospice, and senior living services, expects 2025 revenue between $852.8 mln and $887.6 mln
Pennant projects 2025 adjusted EPS of $1.09 to $1.15
Company anticipates 2025 adjusted EBITDA between $69.1 mln and $72.7 mln
Guidance includes expenses for UnitedHealth, Amedisys transaction
Result Drivers
HOME HEALTH GROWTH - Home health segment revenue rose 32.5% yr/yr, driven by increased admissions
HOSPICE EXPANSION - Hospice average daily census increased 21.4% yr/yr, contributing to revenue growth
SENIOR LIVING REVENUE - Senior living segment revenue grew 23.1% yr/yr, aided by higher revenue per occupied room
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $219.50 mln | $210.60 mln (5 Analysts) |
Q2 Adjusted EPS | Meet | $0.27 | $0.27 (5 Analysts) |
Q2 EPS | $0.2 | ||
Q2 Net Income | $7.10 mln | ||
Q2 Adjusted EBITDA | Beat | $28.20 mln | $16.40 mln (5 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Pennant Group Inc is $33.00, about 32.8% above its August 5 closing price of $22.19
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 22 three months ago
Press Release: ID:nGNXbPXyWw
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)